MASI vs. ITGR, TMDX, LIVN, CNMD, INMD, CYTK, RVMD, STVN, EXEL, and XRAY
Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include Integer (ITGR), TransMedics Group (TMDX), LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Cytokinetics (CYTK), Revolution Medicines (RVMD), Stevanato Group (STVN), Exelixis (EXEL), and DENTSPLY SIRONA (XRAY). These companies are all part of the "medical" sector.
Masimo (NASDAQ:MASI) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Masimo has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
In the previous week, Integer had 3 more articles in the media than Masimo. MarketBeat recorded 18 mentions for Integer and 15 mentions for Masimo. Integer's average media sentiment score of 0.63 beat Masimo's score of 0.56 indicating that Integer is being referred to more favorably in the news media.
Integer has a net margin of 6.01% compared to Masimo's net margin of 4.01%. Masimo's return on equity of 13.26% beat Integer's return on equity.
Masimo received 76 more outperform votes than Integer when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 63.51% of users gave Integer an outperform vote.
86.0% of Masimo shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 2.0% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Integer has lower revenue, but higher earnings than Masimo. Integer is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Masimo presently has a consensus price target of $138.71, suggesting a potential upside of 11.78%. Integer has a consensus price target of $128.67, suggesting a potential upside of 6.41%. Given Masimo's higher probable upside, equities research analysts plainly believe Masimo is more favorable than Integer.
Summary
Masimo and Integer tied by winning 9 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools